EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT ALTERNATING CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER

One way to improve the results of treatment of patients with locally advanced triple-negative breast cancer (TNBC) is to find the most effective neoadjuvant chemotherapy regimen. It has been shown that patients (pts) with TNBC with pathological complete regression (pCR) after neoadjuvant chemotherapy have better survival. The aim of the study was to evaluate the efficacy and toxicity of induction chemotherapy regimen, including 2 consequent chemotherapy regimens: рaclitaxel 60 mg/m²  IV weekly plus сarboplatinum AUC2 IV weekly for 9 weeks, then doxorubicin 25 mg/m² IV weekly plus cyclophosphamide 50 mg per os q. i. d. plus capecitabine 500 mg t. i. d for 9 weeks. The study included 45 patients with TNBC, stages IIIA, IIIB, IIIC. Overall response rate was 40/45 (88,9%) with 7/45 (15,6%) of complete responses and 33/45 (73,3%) of partial responses. Forty-four patients underwent surgery. Twenty seven patients (61,4%) achieved pCR. Three-year disease-free survival was 71% and overall survival was 81%. The most common types of toxicity were neutropenia (40% grade 3–4), mucositis (55% grade 1–3) and hand-foot syndrome (65% grade 1–3). Despite relatively high toxicity this alternating multicomponent induction chemotherapy regimen had high efficacy. More than half of patients (61.4%) achieved pCR.

breast cancer, triple negative phenotype, chemotherapy, pathological complete regression

1. Liedtke C., Mazouni C., Hess K.R. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol., 2008. Vol. 26, No. 8, pp. 1275–1281.

2. Esserman L. J., Berry D. A., De Michele A. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657, J. Clin. Oncol., 2012, Vol. 30, No. 26, pp. 3242–3249.

3. von Minckwitz G., Untch M., Blohmer J.U. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol., 2012, Vol. 30, No. 15, pp. 1796–1804.

4. Стенина М.Б. Принципы лекарственной терапии местнораспространенного и метастатического рака молочной железы // Лекарственная терапия рака молочной железы. 2014. гл. 4. С. 147–160. [Stenina M.B. Printsipy lekarstvennoi terapii mestnorasprostranennogo i metastaticheskogo raka molochnoi zhelezy, Lekarstvennaya terapiya raka molochnoi zhelezy, 2014, gl. 4. pp. 147–160 (In Russ.)].

5. Тюляндин С.А., Стенина М.Б., Фролова М.А. Тройной негативный рак молочной железы // Практическая Онкология. 2010. T. 11. №4. C. 247–252. [Tyulyandin S.A., Stenina M.B., Frolova M.A. Troinoi negativnyi rak molochnoi zhelezy, Prakticheskaya Onkologiya, 2010, Vol. 11, No. 4, pp. 247–252 (In Russ.)].

6. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., Wolff A.C., Sledge G.W., Wood W.C., Davidson N. E. Weekly paclitaxel in the adjuvant treatment of breast cancer, N. Engl. J. Med., 2008, Vol. 358, No. 15., pp. 1663–1671.

7. Citron M. L., Berry D.A., Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741, J. Clin. Oncol., 2003, Vol. 21, No. 8, pp. 1431–1439.

8. Ellis G.K., Barlow W. E., Gralow J.R. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012, J. Clin. Oncol., 2011, Vol. 28, No. 9, pp. 1014–1021.

9. Miller K.D., Sweeney C. J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics, J. Clin. Oncol., 2001, Vol. 19, No. 4, pp. 1195–1206.

10. Seidman A.D., Hudis C.A., Albanell J. et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer, J. Clin. Oncol., 1998, Vol. 16, No. 10, pp. 3353–3361.

11. Muta M., Yanagawa T., Sai Y. et al. Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells, Oncology, 2009, Vol. 77, No. 3-4, pp. 182–91.

12. Benbow U., Maitra R., Hamilton J.W., Brinckerhoff C. E. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin, Clin. Cancer Res., 1999, Vol. 5, No. 1, pp. 203–208.

13. Browder T., Butterfield C. E., Kraling B.M., Shi B., Marshall B., O’Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 2000, Vol. 60, No. 7, pp. 1878–1886.

14. Darb-Esfahani S., Loibl S., Muller B.M. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy, Breast Cancer Res, 2009, Vol. 11, No. 5, R69.

15. Rouzier R., Perou C.M., Symmans W. F. Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin. Cancer Res., 2005, Vol. 11, No. 16, pp. 5678–5685.

16. Carey L.A., Dees E.C., Sawyer L. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin. Cancer Res., 2007, Vol. 13, No. 8, pp. 2329–2334.

17. Torrisi R., Balduzzi A., Ghisini R. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel, Cancer Chemother. Pharmacol., 2008, Vol. 62, No. 4, pp. 667–672.

18. Silver D.P., Richardson A. L., Eklund A.C. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer, J. Clin. Oncol., 2010, Vol. 28, No. 7, pp. 1145–1153.

19. Byrski T., Huzarski T., Dent R. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat., 2014, Vol. 147, No. 2, pp. 401–405.

20. Frasci G., Comella P., Rinaldo M. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer, Ann. Oncol., 2009, Vol. 20, No. 7, pp. 1185–1192.

21. Yerushalmi R., Hayes M.M., Gelmon K.A. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers, Clin. Breast Cancer, 2009, Vol. 9, No. 3, pp. 166–172.

22. Medioni J., Huchon C., Le Frere-Belda M.-A. et al. Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer, Drugs R D, 2011, Vol. 11, No. 2, pp. 147–157.

23. Allred D.C., Harvey J.M., Berardo M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod. Pathol., 1998, Vol. 11, No. 2, pp. 155–168.

24. Bloom H. J., Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br. J. Cancer, 1957, Vol. 11, No. 3, pp. 359–377.

25. Chevallier B., Roche H., Olivier J.P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate, Am. J. Clin. Oncol., 1993, Vol. 16, No. 3, pp. 223–228

26. Frolova M., Skrypnikova M., Ignatova E., Petrovsky A., Stenina M., Ivankina O., Vishnevskaja Y., Tjulandin S. Neoadjuvant chemotherapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in patients with locally advanced (LA) triplenegative breast cancer (TNBC), ASCO Meeting Abstracts, 2013., Vol. 31, No. 15, Р. e12027

27. Скрыпникова М.А. Режимы химиотерапии с модификацией доз и интервалов введения при тройном негативном раке молочной железы: автореф. дис…. канд. мед. наук. М., 2011. 17 с. [Skrypnikova M.A. Rezhimy khimioterapii s modifikatsiei doz i intervalov vvedeniya pri troinom negativnom rake molochnoi zhelezy: Cand. med. sci. thesis, Moscow, 2011, 17 p. (In Russ.)]

28. Sharma P., Lopez-Tarruella S., Garcia-Saenz J.A. et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. Author Manuscript Published, Clin. Cancer Res., 2017, Vol. 23, No. 3, pp. 649–657 pp. 127–181.